Abeona Therapeutics Inc
ABEO
Get informed when a big investor buys or sells
+ FollowMarket Cap$251.61M
Close$
$0.29
93.4% downside
Current Fair Value
93.4% downsideOvervalued by 93.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $251.61 Million |
|---|---|
| Enterprise Value | $215.25 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.34 |
| Beta | 1.3 |
| Outstanding Shares | 57,048,385 |
Return
| Return on Equity | -49.11% |
|---|---|
| Return on Assets | -35.03% |
| Return on Invested Capital | -159.18% |
Valuation & Multiples
| P/E Ratio | -3.88 |
|---|---|
| PEG | 3.27 |
| Price to Sales | - |
| Price to Book Ratio | 2.2 |
| Enterprise Value to Revenue | 8.43 |
| Enterprise Value to EBIT | -0.87 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.23
Average shareholder expectationRevenue Estimate
$12.24 M
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.14
Average shareholder expectationRevenue Estimate
$14.82 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Abeona Therapeutics Inc
226 employees
CEO: Joao Siffert Abeona Therapeutics Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of gene and cell therapies to combat critical, uncommon genetic illnesses. Their foremost developmental asset is EB-101, a pers...